The p53-HDM2 genegene polymorphism interaction is associated with the development of missed abortion

Human Reproduction

Volumn 26, Issue 5, 2011, Pages 1252-1258

  Fang, Yan ^a   Kong, Beihua ^a   Yang, Qifeng ^a   Ma, Daoxin ^a   Qu, Xun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

human double minute 2; missed abortion; p53; polymorphism; pregnancy

Indexed keywords

MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN;

ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSED ABORTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; APOPTOSIS; CHORION VILLUS; CHORION VILLUS SAMPLING; ECHOGRAPHY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PREGNANCY; PROSPECTIVE STUDY;

ABORTION, MISSED; ADULT; APOPTOSIS; CHORIONIC VILLI; CHORIONIC VILLI SAMPLING; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMORPHISM, GENETIC; PREGNANCY; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955372083     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der017     Document Type: Article

References (41)

1. Alarcon-Vargas D, Ronai Z. p53-MDM2-the affair that never ends. Carcinogenesis 2002;23:541-547. (Pubitemid 34498489)
2. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel G, Taubert H, Wuerl P et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602. (Pubitemid 39535748)
3. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-2525. (Pubitemid 28221187)
4. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005;65:1918-1924. (Pubitemid 40478621)
5. Chatzaki E, Makrigiannakis A, Margioris AN, Kouimtzoglou E, Gravanis A. The Fas/FasL apoptosis pathway is involved in kappa-opioid-induced apoptosis of human endometrial stromal cells. Mol Hum Reprod 2001; 7:867-874. (Pubitemid 32842755)
6. Choi HK, Choi BC, Lee SH, Kin JW, Cha KY, Baek KH. Expression of angiogenesis- and apoptosis-related genes in chorionic villi derived from recurrent pregnancy loss patients. Mol Reprod Dev 2003;1:24-31. (Pubitemid 36927783)
7. Coulam CB, Kay C, Jeyendran RS. Role of p53 codon 72 polymorphism in recurrent pregnancy loss. Reprod Biomed Online 2006;12:378-382.
8. Dubs-Poterszman MC, Tocque B, Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 1995;11:2445-2449. (Pubitemid 26008423)
9. Dumont P, Leu JI, Della Pietra ACr, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365. (Pubitemid 36278852)
10. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-1569. (Pubitemid 21905621)
11. Fang Y, Kong B, Yang Q, Ma D, Qu X. MDM2 309 polymorphism is associated with missed abortion. Hum Reprod 2009;6:1346-1349.
12. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins: expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998;43:101-110. (Pubitemid 28103573)
13. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA. Tyrosine phosphorylation of MDM2 by c-Abl : implications for p53 regulation. EMBOJ 2002;21:3715-3727. (Pubitemid 34787045)
14. Griebel CP, Halvorsen J, Golemon T, Day AA. Management of spontaneous abortion. Am Fam Physician 2005;72:1243-1250. (Pubitemid 43104256)
15. Halperin R, Peller S, Rotschild M, Bukvsky I, Schneider D. Placental apoptosis in normal and abnormal pregnancies. Gynecol Obstet Invest 2000;50:84-87.
16. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.
17. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D. The role of p53 and MDM2 polymorphisms in the risk of esophagel squamous cell carcinoma. Cancer Res 2005;65:9582-9587. (Pubitemid 41508029)
18. Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 2008;20:49-55.
19. Hu C, Smith SD, Pang L, Sadovsky Y, Nelson DM. Enhanced basal apoptosis in cultured term human cytotrophoblasts is associated with a higher expression and physical interaction of p53 and Bak. Placenta 2006;27:978-983. (Pubitemid 44204031)
20. Inserra P, Abrahamsen M, Papenfuss M, Giuliano AR. Ethnic variation of the p53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 2003;14:800-804. (Pubitemid 37533138)
21. Jerzak M, Bischof P. Apoptosis in the first trimester human placenta: the role in maintaining immune privilege at the maternal-foetal interface and in the trophoblast remodeling. Eur J Obstet Gynecol Reprod Biol 2002;100:138-142. (Pubitemid 34028130)
22. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of MDM2 in mice reveals a p53-independent role for MDM2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95:15608-15612. (Pubitemid 29018747)
23. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999;96:14973-14977. (Pubitemid 30019749)
24. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-418. (Pubitemid 34164013)
25. Levy R, Smith SD, Yusuf K, Huettner PC, Kraus FT, Sadovsky Y. Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression. Am J Obstet Gynecol 2002;186:1056-1061.
26. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001;98:11598-11603. (Pubitemid 32928774)
27. Michael D, Oren M. The p53 and MDM2 families in cancer. Curr Opin Genet Dev 2002;12:53-59. (Pubitemid 34094990)
28. Michael D, Oren M. The p53-MDM2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58. (Pubitemid 36269180)
29. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-4440. (Pubitemid 46630981)
30. Pietrowski D, Tempfer C, Bettendorf H, Bürkle B, Nagele F, Unfried G, Keck C. Angiopoietin-2 polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril 2003;4:1026-1029. (Pubitemid 37230043)
31. Pietrowski D, Bettendorf H, Riener EK, Keck C, Hefler LA, Huber JC, Tempfer C. Recurrent pregnancy failure is associated with a polymorphism in the p53 tumor suppressor gene. Hum Reprod 2005; 4:848-851. (Pubitemid 40667827)
32. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-199. (Pubitemid 37541770)
33. Qiao S, Nagasaka T, Harada T, Nakashima N. p53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta 1998;19:361-369. (Pubitemid 28327694)
34. Quenby S, Brazeau C, Drakeley A, Lewis-Jones DI, Vince G. Oncogene and tumour suppressor gene products during trophoblast differentiation in the first trimester. Mol Hum Reprod 1998;4:477-481. (Pubitemid 28253208)
35. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F. Opposing effects of Ras on p53: transcriptional activation of MDM2 and induction of p19ARF. Cell 2000;103:321-330.
36. Savion S, Lepsky E, Orenstein H, Carp H, Shepshelovich J, Torchinsky A, Fein A, Toder V. Apoptosis in the uterus of mice with pregnancy loss. Am J Reprod Immunol 2002;47:118-127. (Pubitemid 34552384)
37. Sivaraman L, Conneely OM, Medina D, BW OM. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001;98:12379-12384. (Pubitemid 33019954)
38. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100. (Pubitemid 29046852)
39. Wu X, Bayle JH, Olson D, Levine AJ. The p53-MDM2-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
40. Yoon YJ, Chang HY, Ahn SH, Kin JK, Kang DR, Park JY. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29:1192-1196. (Pubitemid 351964880)
41. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human MDM2 gene. Nucleic Acids Res 1995;23:2584-2592.